Merck's powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new use

Right now, Roche’s Tecentriq is the only immuno-oncology drug approved in triple negative breast cancer. And thanks to a rare trial miss for Merck's superstar Keytruda, it looks like it’ll stay that way for awhile.